Ligand Pharmaceuticals
Ligand Pharmaceuticals manages a diverse portfolio of biopharmaceutical royalties, owns economic rights to over 25 commercial programs worldwide, and licenses the Captisol technology for drug development.
Services
Ligand Pharmaceuticals manages a large and diverse portfolio of biopharmaceutical royalties, encompassing more than 85 commercial and development stage programs. The company invests in the clinical development and commercialization of high-value medicines. Ligand licenses the Captisol technology platform, which aids broadly in drug development.
Biopharmaceutical Royalties Portfolio
Ligand Pharmaceuticals manages one of the most extensive portfolios of biopharmaceutical royalties, with over 85 partnered commercial and development stage programs. The company holds economic rights to more than 25 commercial programs that are marketed in over 70 countries. This portfolio includes treatments for a range of conditions such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and numerous rare diseases.
Captisol Technology Platform
The Captisol technology platform is a key asset of Ligand Pharmaceuticals. This platform is widely used in drug development to enhance the solubility and stability of active pharmaceutical ingredients. Ligand licenses this technology to various pharmaceutical companies to facilitate the development and optimization of therapeutic drugs.
Strategic Acquisitions and Agreements
Ligand Pharmaceuticals has made significant strategic moves to bolster its portfolio and capabilities. The company acquired Tolerance Therapeutics for $20 million in cash, gaining royalties on worldwide net sales of TZIELD. Additionally, Ligand entered into a $30 million agreement with Ovid Therapeutics for royalties and milestones related to Takeda’s soticlestat, aimed at treating Lennox-Gastaut syndrome and Dravet syndrome. Furthermore, the company secured a $100 million royalty financing agreement with Agenus.
Therapeutic Areas
The portfolio of Ligand Pharmaceuticals includes treatments across various therapeutic areas. Key focus areas are solutions for diseases such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and a range of rare conditions. Their investment and development efforts are directed towards bringing high-value medicines to market to address these significant health challenges.